后皮质萎缩的诊断和管理。

IF 2 4区 医学 Q1 Medicine
Current Treatment Options in Neurology Pub Date : 2023-01-01 Epub Date: 2023-02-08 DOI:10.1007/s11940-022-00745-0
Keir X X Yong, Jonathan Graff-Radford, Samrah Ahmed, Marianne Chapleau, Rik Ossenkoppele, Deepti Putcha, Gil D Rabinovici, Aida Suarez-Gonzalez, Jonathan M Schott, Sebastian Crutch, Emma Harding
{"title":"后皮质萎缩的诊断和管理。","authors":"Keir X X Yong, Jonathan Graff-Radford, Samrah Ahmed, Marianne Chapleau, Rik Ossenkoppele, Deepti Putcha, Gil D Rabinovici, Aida Suarez-Gonzalez, Jonathan M Schott, Sebastian Crutch, Emma Harding","doi":"10.1007/s11940-022-00745-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>The study aims to provide a summary of recent developments for diagnosing and managing posterior cortical atrophy (PCA). We present current efforts to improve PCA characterisation and recommendations regarding use of clinical, neuropsychological and biomarker methods in PCA diagnosis and management and highlight current knowledge gaps.</p><p><strong>Recent findings: </strong>Recent multi-centre consensus recommendations provide PCA criteria with implications for different management strategies (e.g. targeting clinical features and/or disease). Studies emphasise the preponderance of primary or co-existing Alzheimer's disease (AD) pathology underpinning PCA. Evidence of approaches to manage PCA symptoms is largely derived from small studies.</p><p><strong>Summary: </strong>PCA diagnosis is frequently delayed, and people are likely to receive misdiagnoses of ocular or psychological conditions. Current treatment of PCA is symptomatic - pharmacological and non-pharmacological - and the use of most treatment options is based on small studies or expert opinion. Recommendations for non-pharmacological approaches include interdisciplinary management tailored to the PCA clinical profile - visual-spatial - rather than memory-led, predominantly young onset - and psychosocial implications. Whilst emerging disease-modifying treatments have not been tested in PCA, an accurate and timely diagnosis of PCA and determining underlying pathology is of increasing importance in the advent of disease-modifying therapies for AD and other albeit rare causes of PCA.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":"25 2","pages":"23-43"},"PeriodicalIF":2.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935654/pdf/","citationCount":"0","resultStr":"{\"title\":\"Diagnosis and Management of Posterior Cortical Atrophy.\",\"authors\":\"Keir X X Yong, Jonathan Graff-Radford, Samrah Ahmed, Marianne Chapleau, Rik Ossenkoppele, Deepti Putcha, Gil D Rabinovici, Aida Suarez-Gonzalez, Jonathan M Schott, Sebastian Crutch, Emma Harding\",\"doi\":\"10.1007/s11940-022-00745-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>The study aims to provide a summary of recent developments for diagnosing and managing posterior cortical atrophy (PCA). We present current efforts to improve PCA characterisation and recommendations regarding use of clinical, neuropsychological and biomarker methods in PCA diagnosis and management and highlight current knowledge gaps.</p><p><strong>Recent findings: </strong>Recent multi-centre consensus recommendations provide PCA criteria with implications for different management strategies (e.g. targeting clinical features and/or disease). Studies emphasise the preponderance of primary or co-existing Alzheimer's disease (AD) pathology underpinning PCA. Evidence of approaches to manage PCA symptoms is largely derived from small studies.</p><p><strong>Summary: </strong>PCA diagnosis is frequently delayed, and people are likely to receive misdiagnoses of ocular or psychological conditions. Current treatment of PCA is symptomatic - pharmacological and non-pharmacological - and the use of most treatment options is based on small studies or expert opinion. Recommendations for non-pharmacological approaches include interdisciplinary management tailored to the PCA clinical profile - visual-spatial - rather than memory-led, predominantly young onset - and psychosocial implications. Whilst emerging disease-modifying treatments have not been tested in PCA, an accurate and timely diagnosis of PCA and determining underlying pathology is of increasing importance in the advent of disease-modifying therapies for AD and other albeit rare causes of PCA.</p>\",\"PeriodicalId\":10975,\"journal\":{\"name\":\"Current Treatment Options in Neurology\",\"volume\":\"25 2\",\"pages\":\"23-43\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935654/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Treatment Options in Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11940-022-00745-0\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/2/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Treatment Options in Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11940-022-00745-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/2/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

综述的目的:本研究旨在总结诊断和管理后皮质萎缩(PCA)的最新进展。我们介绍了当前为改善 PCA 特征所做的努力,以及在 PCA 诊断和管理中使用临床、神经心理学和生物标志物方法的建议,并强调了当前的知识差距:最近的多中心共识建议为不同的管理策略(如针对临床特征和/或疾病)提供了PCA标准。研究强调,原发性或并存的阿尔茨海默病(AD)病理是 PCA 的主要病因。有关 PCA 症状管理方法的证据主要来自小型研究。摘要:PCA 的诊断经常被延误,患者很可能被误诊为眼部或心理疾病。目前对 PCA 的治疗主要是对症治疗--药物治疗和非药物治疗--大多数治疗方案的使用都是基于小型研究或专家意见。对非药物治疗方法的建议包括针对 PCA 临床特征(视觉-空间-而非记忆主导,主要在年轻时发病)和社会心理影响的跨学科管理。虽然新出现的改变疾病的治疗方法尚未在 PCA 中进行过测试,但准确、及时地诊断 PCA 并确定潜在的病理变化,对于针对注意力缺失症和其他尽管罕见的 PCA 病因的改变疾病的治疗方法的出现具有越来越重要的意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Diagnosis and Management of Posterior Cortical Atrophy.

Diagnosis and Management of Posterior Cortical Atrophy.

Purpose of review: The study aims to provide a summary of recent developments for diagnosing and managing posterior cortical atrophy (PCA). We present current efforts to improve PCA characterisation and recommendations regarding use of clinical, neuropsychological and biomarker methods in PCA diagnosis and management and highlight current knowledge gaps.

Recent findings: Recent multi-centre consensus recommendations provide PCA criteria with implications for different management strategies (e.g. targeting clinical features and/or disease). Studies emphasise the preponderance of primary or co-existing Alzheimer's disease (AD) pathology underpinning PCA. Evidence of approaches to manage PCA symptoms is largely derived from small studies.

Summary: PCA diagnosis is frequently delayed, and people are likely to receive misdiagnoses of ocular or psychological conditions. Current treatment of PCA is symptomatic - pharmacological and non-pharmacological - and the use of most treatment options is based on small studies or expert opinion. Recommendations for non-pharmacological approaches include interdisciplinary management tailored to the PCA clinical profile - visual-spatial - rather than memory-led, predominantly young onset - and psychosocial implications. Whilst emerging disease-modifying treatments have not been tested in PCA, an accurate and timely diagnosis of PCA and determining underlying pathology is of increasing importance in the advent of disease-modifying therapies for AD and other albeit rare causes of PCA.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.00
自引率
0.00%
发文量
40
审稿时长
6-12 weeks
期刊介绍: This journal aims to review the most important, recently published treatment option advances in the field of neurology. By presenting clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to the treatment of neurologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as epilepsy, headache, neurologic ophthalmology and otology, neuromuscular disorders, psychiatric manifestations of neurologic disease, and sleep disorders. Section Editors select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known neurologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信